BioCryst influenza treatment OK'd in Canada
Research Triangle Park, N.C. — RTP-based BioCryst Pharmaceuticals has received approval to sell its influenza treatment in Canada. It's now available in five countries.
BioCryst (Nasdaq: BCRX) announced the approval Sunday.
The company's treamtnet known as Rapivab is an intravenous treatment for acute, uncomplicated influenza. It's already approved in the U.S.
The drug is being commercialized by BioCryst partner Seqirus.
Other partners are selling the drug in Japan, Taiwan and South Korea.
“This RAPIVAB approval represents an important milestone for BioCryst and for our partner, Seqirus,” said BioCryst CEO Jon Stonehouse. “We are excited that patients in Canada will soon have an I.V. option for the treatment of influenza infections.”
BioCryst has a number of other treatments under development.
Please Log In to add a comment.
Latest for Insiders
- Think you know millennials? Case survey runs counter to narrative with Trump, conservatism scoring well
- After Trump meeting, Bayer-Monsanto pledge could mean jobs in RTP
- Birthday (unofficial): The soft launch of Local Tech Wire
- RTI International revenues, work force surge in 2016
- Reports: Lenovo seeking full ownership of laptop joint venture
- American Underground rolls out 'new product offering for a new audience'
- Third VC report confirms trend: VC boom is over in NC
- US sales growth helps Lenovo keep global PC sales lead
- Boom over: Venture reports agree dealmaking drops in 2016
- Fast-growing Walk West agency adds another firm in 'digital first' strategy